Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 18;25(20):11207.
doi: 10.3390/ijms252011207.

An Inexpensive and Quick Method for Genotyping of HLA Variants Included in the Spanish Pharmacogenomic Portfolio of National Health System

Irene Taladriz-Sender  1 , Gina Hernández-Osio  1 , Paula Zapata-Cobo  1 , Sara Salvador-Martín  1 , Xandra García-González  1 , Antonio Balas  2 , María Sanjurjo-Sáez  1 , Luis A López-Fernández  1
Affiliations

An Inexpensive and Quick Method for Genotyping of HLA Variants Included in the Spanish Pharmacogenomic Portfolio of National Health System

Irene Taladriz-Sender et al. Int J Mol Sci. .

Abstract

The possibility of using the same genotyping technology (TaqMan) for all the genetic tests included in the new Spanish pharmacogenomics portfolio should enable the application of a multigenotyping platform to obtain a whole pharmacogenomics profile. However, HLA-typing is usually performed with other technologies and needs to be adapted to TaqMan assays. Our aim was to establish a set of TaqMan assays for correct typing of HLA-A*31:01, HLA-B*15:02, HLA-B*57:01, and HLA-B*58:01. Therefore, we searched for and selected SNVs described in different populations as surrogate markers for these HLA alleles, designed TaqMan assays, and tested in a set of samples with known HLA-A and HLA-B. HLA-A*31:01 was correctly typed with a combination of rs1061235 and rs17179220 (PPV 100%, 95% CI 84.6-100-%; NPV 100%, 95% CI 96.5-100.0%), HLA-B*15:02 with rs10484555 (PPV 100%, 95% CI 69.2-100.0%; NPV 100%, 95% CI 96.8-100.0%) and rs144012689 (PPV 100%, 95% CI 69.2-100.0%; NPV 100%, 95% CI 96.8-100.0%), and HLA-B*57:01 with rs2395029 (PPV 99.5%, 95% CI 72.9-99.3%; NPV 99.5%, 95% CI 98.3-100.0%). HLA-B*58:01 was typed using two allele-specific TaqMan probes mixed with a ß-Globin reference and treated as a genotyping assay (PPV 100.0%, 95% CI 81.5-100.0%; NPV 100%, 95% CI 96.8-100.0%). In conclusion, we demonstrated a clinically useful way to type HLA-A and HLA-B alleles included in the Spanish pharmacogenomics portfolio using TaqMan assays.

Keywords: HLA-typing; genotyping; pharmacogenetics; pharmacogenomics.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Allelic discrimination and amplification plots for specifically designed HLA-B*58:01 assays. Carriers of HLA-B*5801 were perfectly clustered. The figure shows the results of the following: (a) the allelic discrimination plot assay for 5801A (green, HLA-B*5801 positive and ß-Globin positive; blue, HLA-B*5801 negative and ß-Globin positive); (b) the allelic discrimination plot assay for 5801B (green, HLA-B*5801 positive and ß-Globin positive; blue, HLA-B*5801 negative and ß-Globin positive); (c) the amplification plot assay for 5801A (purple, ß-Globin, orange, HLA-B*5801); and (d) the amplification plot assay for 5801B (green, ß-Globin; red, HLA-B*5801).
See this image and copyright information in PMC

References

    1. Abad-Santos F., Aliño S.F., Borobia A.M., García-Martín E., Gassó P., Maroñas O., Agúndez J.A. Developments in Pharmacogenetics, Pharmacogenomics, and Personalized Medicine. Pharmacol. Res. 2024;200:107061. doi: 10.1016/j.phrs.2024.107061. - DOI - PubMed
    1. Sebastian A., Migalska M., Biedrzycka A. AmpliSAS and AmpliHLA: Web Server Tools for MHC Typing of Non-Model Species and Human Using NGS Data. Methods Mol. Biol. 2018;1802:249–273. - PubMed
    1. Profaizer T., Pole A., Monds C., Delgado J.C., Lázár-Molnár E. Clinical utility of next generation sequencing based HLA typing for disease association and pharmacogenetic testing. Hum. Immunol. 2020;81:354–360. doi: 10.1016/j.humimm.2020.05.001. - DOI - PubMed
    1. Buhler S., Nørgaard M., Steffensen R., Kløve-Mogensen K., Møller B.K., Grossmann R., Ferrari-Lacraz S., Lehmann C. High resolution HLA genotyping with third generation sequencing technology—A multicentre study. HLA. 2024;104:e15632. doi: 10.1111/tan.15632. - DOI - PubMed
    1. Tsukagoshi E., Nakamura R., Tanaka Y., Maekawa K., Hiratsuka M., Asada H., Saito Y. Validation of a genotyping technique for a surrogate marker of HLA-B*58:01 for allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in the Japanese population. Drug Metab. Pharmacokinet. 2023;49:100495. doi: 10.1016/j.dmpk.2023.100495. - DOI - PubMed

LinkOut - more resources